Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.69 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | IL18 | Q14116 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11768213 | 0.90 | SAE1 (0.58) | SAE1UBA2MAPTLMNATSHR | |
| SCHEMBL11054945 | 0.88 | MAPT (0.81) | SAE1UBA2MAPTLMNATSHR | |
| SCHEMBL10155599 | 0.83 | ALDH1A1 (0.78) | SAE1UBA2MAPTTSHRKMT2A | |
| SCHEMBL7344351 | 0.83 | PLAU (0.61) | SAE1UBA2MAPTLMNATSHR | |
| SCHEMBL11054936 | 0.83 | MAPT (0.69) | SAE1UBA2MAPTLMNATSHR | |
| SCHEMBL10586455 | 0.82 | ALDH1A1 (0.60) | SAE1UBA2MAPTLMNATSHR | |
| SCHEMBL1542345 | 0.81 | ALDH1A1 (0.58) | SAE1UBA2MAPTLMNATSHR | |
| SCHEMBL11056656 | 0.81 | MAPT (0.75) | SAE1UBA2MAPTLMNATSHR | |
| SCHEMBL28454806 | 0.81 | GPR35 (0.59) | SAE1UBA2MAPTLMNATSHR | |
| SCHEMBL9483831 | 0.81 | CA12 (0.54) | SAE1UBA2LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3974423-A1 | INDOLE DERIVATIVE-CONTAINING INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2022-03-30 | — | — | EP | disclosed |
| US-10556889-B1 | Salvinorin derivatives | Blue Sky Pharmaceuticals, LLC (US) | 2020-02-11 | — | — | US | disclosed |
| US-8569267-B2 | Tetracyclic tetrahydrofuran derivatives containing cyclic amine side chain | JANSSEN PHARMACEUTICA, NV (BE) | 2013-10-29 | — | — | US | disclosed |
| EP-1930319-B1 | Proline derivatives and use thereof as drugs | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20080262076-A1 | Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain | JANSSEN PHARMACEUTICA, NV (BE) | 2008-10-23 | — | — | US | disclosed |
| US-20080262076-A1 | Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain | JANSSEN PHARMACEUTICA, NV (BE) | 2008-10-23 | — | — | US | disclosed |
| EP-1308439-B1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1930319-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-5807875-A | OBESITY THERAPY | DR. KARL THOMAE GMBH (DE) | 1998-09-15 | — | — | US | disclosed |
| US-5616620-A | HYPOTENSIVE AGENTS | KARL THOMAE GMBH (DE) | 1997-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262076-A1 | Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain | HTR2C, HTR2A, HTR5A | SAE1 2244/4885UBA2 993/4885MAPT 3030/4885 |
| US-10556889-B1 | Salvinorin derivatives | OPRD1, OPRK1, OPRL1 | SAE1 483/4885UBA2 1629/4885MAPT 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.